Education
What we tell patients, written down.
No hype, no supplement funnels. Straight explanations of the medicine behind hormone optimization and peptide therapy.
Clinical commentary
Peptide Compounding Is Being Reopened: Where It Actually Stands
FDA pulled twelve peptides off its do-not-compound category, its advisory committee recommended six for the 503A list, and HHS is reported to be preparing a stopgap. None of it has made a single peptide lawfully compoundable yet. Here is what each step actually did.
Read →Clinical commentary
What the Empower Warning Letter Means for Prescribers
FDA's September 2026 Warning Letter to Empower Pharmacy set out a method for identifying pretext in compounded GLP-1 prescribing. Most of the evidence it relies on is generated in the prescriber's office.
Read →A founder's routine
Energy at 55
The daily routine I run at 55. Not a prescription — just what I do, in order, every day.
Read →Reading your bloodwork
You weren’t told you’re healthy. You were told you’re average.
A reference range is the middle 95% of a population that has been getting metabolically sicker for thirty years — plus the full marker panel we run for men and women.
Read →For women
Perimenopause is not something you have to ride out
Hot flashes, 3 a.m. wake-ups, brain fog and lost libido are downstream of measurable hormonal change — and measurable change is treatable.
Read →For men
TRT in Chicago: what to actually expect
What gets tested, what the first ninety days feel like, what gets monitored, and the questions worth asking any clinic before you start.
Read →Research peptides
How research-use-only peptides are made, tested and handled
A physician-reviewed library on manufacturing, testing, legality and what actually goes wrong. Start at the overview →
The chain of custody behind a finished vial
Six checkpoints from qualified raw material through independent testing, with a record attached to every stage.
Read →How a peptide is actually made
Synthesis, purification, nine release tests, sterile fill, batch release and cold chain — and what has to pass at each stage.
Read →Is it legal to buy research-use-only peptides?
Selling, possessing and self-administering are three different legal questions. What the disclaimer settles, and what it does not.
Read →Research-use-only vs. prescribed peptides
The mechanisms that actually differ — licensure, lot release, verification, recall — and the one thing that often does not.
Read →What a certificate of analysis can and cannot establish
Purity versus net peptide content, what the document omits, and why a CoA is a manufacturing record rather than a safety finding.
Read →What purity doesn't tell you: sterility and endotoxin
Three separate properties, three separate tests. Why a purity figure says nothing about what happens after an injection.
Read →What actually goes wrong
Documented failure modes: dosing arithmetic, injection-site infection, mislabeled or degraded material, and what monitoring catches.
Read →